Nektar Therapeutics (NKTR)
(Real Time Quote from BATS)
$22.48 USD
-0.08 (-0.36%)
Updated Aug 6, 2025 03:54 PM ET
After-Market: $22.51 +0.03 (0.13%) 4:12 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NKTR 22.48 -0.08(-0.36%)
Will NKTR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NKTR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NKTR
Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates
Nektar Gears Up to Report Q2 Earnings: What's in the Cards?
NKTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
Other News for NKTR
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After ...
Nektar gets FDA fast track status for alopecia areata drug
Nektar (NKTR) Gains FDA Fast Track Status for Alopecia Areata Treatment
Nektar's rezpegaldesleukin granted Fast Track Designation in alopecia areata
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of ...